Thermo Fisher Scientific Inc. officially completed its US$4.0 billion acquisition of Solventum’s purification and filtration business. Following the deal, the unit will operate as Thermo Fisher’s Filtration and Separation business within its Life Sciences Solutions segment.
Strengthening Bioproduction Capabilities
The acquisition adds a strong portfolio of bioprocessing, healthcare, and industrial filtration solutions, along with advanced membranes. These technologies will bolster Thermo Fisher’s bioproduction offerings, enhancing quality and efficiency across both upstream and downstream workflows.
Expanding into High-Growth Industries
Beyond bioprocessing, the addition also opens doors to new markets. The industrial filtration and membrane solutions will help Thermo Fisher expand into industries requiring ultra-pure water, such as battery production, semiconductor manufacturing, and medical devices. For the full year 2025, the business is projected to deliver approximately US$750 million in revenue.
CEO’s Perspective on Growth Potential
Marc Casper, Chairman, President, and CEO, Thermo Fisher, stated, “We are delighted to welcome the Filtration and Separation colleagues to Thermo Fisher. The addition of innovative filtration technologies is highly complementary and expands our bioprocessing portfolio to better serve the end-to-end needs of our pharma and biotech customers in this rapidly growing market. It also provides opportunities to broaden our reach in adjacent markets with attractive growth.”
